Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0BRCRW
ADC Name
CCR4-IL2 IT
Synonyms
CCR4-IL2-IT; CCR4-IL2IT
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Cutaneous T-cell lymphoma [ICD11:2B00]
Investigative
Antibody Name
CCR4IL2
  Antibody Info 
Antigen Name
C-C chemokine receptor type 4 (CCR4)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.45
pM
HUT102/6TG cells
Cutaneous T cell lymphoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.45 pM Positive CCR4 expression (CCR4 +++/++)
Method Description
A comparison of the in vitro efficacy of CCR4-IL2 IT versus brentuximab to human CD25+CCR4+CD30+ Hut102/6TG cells was performed using a luminescent-based cell viability assay.
In Vitro Model Cutaneous T cell lymphoma HUT102/6TG cells Homo sapiens
References
Ref 1 CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 Jul;13(7):1309-1319. doi: 10.1002/2211-5463.13625. Epub 2023 May 15.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.